Graves' disease is an autoimmune disorder and the most common cause of hyperthyroidism, accounting for 60–80% of all cases. It occurs when the immune system produces antibodies that mimic TSH, causing the thyroid gland to grow and produce excessive amounts of thyroid hormone.

The Autoimmune Mechanism

In Graves' disease, the immune system produces abnormal antibodies called thyroid-stimulating immunoglobulins (TSI) or TSH receptor antibodies (TRAb). These antibodies bind to TSH receptors on the thyroid and continuously stimulate it — unlike TSH, which rises and falls naturally, these antibodies provide unregulated, constant stimulation that overrides the body's normal feedback controls.

Who Gets Graves' Disease?

Graves' disease is more common in women than men (7:1 ratio) and typically develops between ages 20 and 50. Genetic predisposition plays a role — it often runs in families. Environmental triggers, including stress, pregnancy, infection, and smoking, may trigger onset in susceptible individuals. Smoking is a particularly important risk factor for the development of Graves' eye disease.

Symptoms of Graves' Disease

Symptoms include all the signs of hyperthyroidism (palpitations, weight loss, heat intolerance, anxiety, tremor), plus three manifestations that are unique to Graves' disease:

  • Diffuse goiter — Smooth, symmetrical enlargement of the entire thyroid gland
  • Graves' ophthalmopathy (thyroid eye disease) — Eye changes including bulging eyes (proptosis), double vision, eye pain, and light sensitivity
  • Pretibial myxedema — Thickening and reddening of the skin on the shins (rare)

👁ïļ Graves' Eye Disease: About 25–30% of people with Graves' disease develop some degree of thyroid eye disease. In most cases it is mild, but it can occasionally cause significant vision problems. Smoking dramatically worsens Graves' eye disease — quitting smoking is essential.

Diagnosis

Diagnosis involves blood tests showing low TSH and elevated free T4/T3, plus positive TSI or TRAb antibodies. Thyroid ultrasound typically shows an enlarged, hyperactive gland. Radioactive iodine uptake scan shows diffusely elevated uptake throughout the gland.

Treatment

All three treatment options for hyperthyroidism apply to Graves' disease:

  • Antithyroid drugs (ATDs): Methimazole is the preferred agent. About 30–40% of patients achieve long-term remission with 12–18 months of treatment. Relapse is common after stopping medication.
  • Radioactive iodine (RAI): Most patients become hypothyroid after RAI and require lifelong levothyroxine. RAI may worsen Graves' eye disease and should be used with caution in patients with active ophthalmopathy.
  • Thyroidectomy: Total thyroidectomy is curative and may be preferred in patients with large goiters, severe eye disease, or who wish to avoid RAI.

During initial treatment, beta-blockers (propranolol, atenolol) are often prescribed to quickly control symptoms like heart palpitations and tremor while thyroid hormone levels normalize.

Key Takeaways

  • Graves' disease is the most common cause of hyperthyroidism — it's an autoimmune condition
  • Unique features include diffuse goiter and potential eye disease (Graves' ophthalmopathy)
  • TSI/TRAb antibodies confirm the diagnosis
  • Treatment options include antithyroid drugs, radioactive iodine, and surgery
  • Smoking worsens Graves' eye disease — cessation is critical
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making any changes to your treatment plan. Individual medical decisions should be made in partnership with your physician based on your specific circumstances.